The charts on this page feature a breakdown of the total annual pay for the top executives at BIOGEN INC. as reported in their proxy statements.

Total Cash Compensation information is comprised of yearly Base Pay and Bonuses. BIOGEN INC. income statements for executive base pay and bonus are filed yearly with the SEC in the edgar filing system. BIOGEN INC. annual reports of executive compensation and pay are most commonly found in the Def 14a documents.

Total Equity aggregates grant date fair value of stock and option awards and long term incentives granted during the fiscal year.

Other Compensation covers all compensation-like awards that don't fit in any of these other standard categories. Numbers reported do not include change in pension value and non-qualified deferred compensation earnings.

Name And Title Total Cash Equity Other Total Compensation
Susan H. Alexander
Executive Vice President, Chief Legal Officer And Secretary
Total Cash $1,416,087 Equity $3,583,281 Other $159,261 Total Compensation $5,158,629
Alfred W. Sandrock Jr.
Executive Vice President, Research & Development
Total Cash $1,609,851 Equity $4,331,654 Other $147,020 Total Compensation $6,088,525
Jeffrey D. Capello
Former Executive Vice President and Chief Financial Officer
Total Cash $671,132 Equity $3,901,503 Other $4,648,876 Total Compensation $9,221,511
Michel Vounatsos
Chief Executive Officer
Total Cash $4,053,462 Equity $13,887,064 Other $454,945 Total Compensation $18,395,471
Chirfi Guindo
Executive Vice President, Global Product Strategy and Commercialization
Total Cash $1,090,789 Equity $3,961,285 Other $80,721 Total Compensation $5,132,795
Michael R. McDonnell
Executive Vice President and Chief Financial Officer
Total Cash $1,557,553 Equity $5,012,308 Other $5,696 Total Compensation $6,575,557
For its 2020 fiscal year, BIOGEN INC., listed the following CEO pay ratio data on its annual proxy statement to the SEC.
CEO Name CEO Pay Median Employee Pay CEO Pay Ratio
Michel Vounatsos CEO Pay $18,659,829 Median Employee Pay $155,378 CEO Pay Ratio 120:1
For its 2020 fiscal year, BIOGEN INC., listed the following board members on its annual proxy statement to the SEC.
Name Total COMPENSATION
Alexander J. Denner Total Cash $439,314
Brian S. Posner Total Cash $434,314
Caroline D. Dorsa Total Cash $424,314
Eric K. Rowinsky Total Cash $409,314
Jesus B. Mantas Total Cash $409,314
Lynn Schenk Total Cash $95,000
Nancy L. Leaming Total Cash $437,814
Richard C. Mulligan Total Cash $409,314
Robert W. Pangia Total Cash $529,204
Stelios Papadopoulos Total Cash $669,822
Stephen A. Sherwin Total Cash $409,314
William A. Hawkins Total Cash $409,314

This report is not for commercial use. Thorough reviews have been conducted to assure this data accurately reflects disclosures. However for a complete and definitive understanding of the pay practices of any company, users should refer directly to the actual, complete proxy statement.

The information shown here is a reporting of information included in the company's proxy statement. The proxy statement includes footnotes and explanations of this information plus other information that is pertinent in assessing the overall value and appropriateness of the compensation information. For those interested in conducting a detailed compensation analysis, we recommend that you review the entire proxy statement. You may retrieve the full proxy statement by going to the Securities and Exchange Commission (SEC) website at www.sec.gov and entering the company's name and then looking in the first column for an entry of "Form DEF 14A" (or any similar code). You may also find the annual proxy statement by going directly to the company's website.

A proxy statement (or "proxy") is a form that every publicly traded U.S. company is required to file with the U.S. Securities & Exchange Commission (SEC) within 120 days after the end of its fiscal year. The proxy must be sent to every shareholder in advance of the company's annual shareholders meeting. All proxy statements are public filings made available to the general public by the SEC.

The proxy statement's main purpose is to alert shareholders to the annual meeting and provide them information about the issues that will be voted on during the annual meeting, including decisions such as electing directors, ratifying the selection of auditors, and other shareholder-related decisions, including shareholder-initiated initiatives. Also, proxies must disclose specific detailed information regarding the pay practices for certain executives.